Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC [0.03%]
联盟基金会试验09：一项随机、多中心、二期临床试验，评估派姆单抗和标准铂类化疗两种顺序在转移性非小细胞肺癌患者中的疗效
Thomas A Hensing,Xiaofei Wang,Thomas E Stinchcombe et al.
Thomas A Hensing et al.
Introduction: The sequence of chemotherapy and pembrolizumab may affect antitumor immune response and efficacy of immunotherapy. Methods: ...
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 [0.03%]
派姆单抗单一疗法在程序性死亡配体1阳性非小细胞肺癌并伴有脑转移的患者的治疗结果：KEYNOTE-001，010，024和042的综合分析
Aaron S Mansfield,Roy S Herbst,Gilberto de Castro Jr et al.
Aaron S Mansfield et al.
Introduction: We retrospectively evaluated outcomes in patients with programmed death-ligand 1 (PD-L1)-positive non-small-cell lung cancer (NSCLC) to determine whether baseline (i.e., at study enrollment) brain metastases...
Hypercalcemia Owing to Overproduction of 1,25-Dihydroxyvitamin D3 in Fetal Lung Adenocarcinoma: Case Report [0.03%]
胎儿型肺腺癌导致的高钙血症：病例报告
Tomohito Saito,Mistuaki Ishida,Makiko Kusabe et al.
Tomohito Saito et al.
Hypercalcemia is a common electrolyte abnormality in malignancy and is largely caused by activation of parathyroid hormone (PTH) pathways. We report the case of a 76-year-old man with hypercalcemia primarily owing to 1,25-dihydroxyvitamin D...
Survival Impact of an Enhanced Multidisciplinary Thoracic Oncology Conference in a Regional Community Health Care System [0.03%]
区域性社区卫生系统中强化的多学科胸科肿瘤会议对生存率的影响
Meredith A Ray,Nicholas R Faris,Carrie Fehnel et al.
Meredith A Ray et al.
Introduction: We compared NSCLC treatment and survival within and outside a multidisciplinary model of care from a large community health care system. Met...
Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report [0.03%]
BRAF K601E突变阳性肺腺癌患者对达拉非尼和曲美替尼联合治疗的持久反应一例报告
Po-Lan Su,Chien-Yu Lin,Yi-Lin Chen et al.
Po-Lan Su et al.
Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with NSCLC with a BRAF V600E mutation. Nevertheless, the treatment strategy for patients with NSCLC with BRAF non-V600E mutati...
Optimal Radiation Dose for Stage III Lung Cancer-Should "Definitive" Radiation Doses Be Used in the Preoperative Setting? [0.03%]
III期肺癌的最优放射剂量——术前放射治疗应使用“确定性”的放射剂量吗？
Areo G Saffarzadeh,Maureen Canavan,Benjamin J Resio et al.
Areo G Saffarzadeh et al.
Introduction: There are currently two recommended radiation strategies for clinical stage III NSCLC: a lower "preoperative" (45-54 Gy) and a higher "definitive/nonsurgical" (60-70 Gy) dose. We sought to determine if defin...
Evaluating the Content Validity, Clarity, and Relevance of Two Patient-Reported Outcomes for Use With Adults With EGFR-Mutated NSCLC [0.03%]
两种患者报告结局评价其内容效度、清晰度和与成年EGFR突变型非小细胞肺癌的相关性研究
Marcia K Horn,Kevin Liu,Susan D Mathias et al.
Marcia K Horn et al.
Introduction: NSCLCs account for most lung cancers; approximately 30% involve a mutation in the EGFR gene. This study sought to identify one or more patient-reported outcome (PRO) measures relevant for use in clinical tri...
Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC [0.03%]
早期停用durvalumab与III期非小细胞肺癌患者生存率低的关联
Narek Shaverdian,Michael Offin,Annemarie F Shepherd et al.
Narek Shaverdian et al.
Introduction: Durvalumab after concurrent chemoradiation (cCRT) has been found to improve outcomes of patients with unresected stage III NSCLC. However, the survival impact of discontinuing durvalumab early owing to adver...
Clinical Characteristics and Molecular Profiles of Lung Cancer in Ethiopia [0.03%]
埃塞俄比亚肺癌的临床特点和分子特征
Tewodros H Gebremariam,Deborah A Haisch,Helen Fernandes et al.
Tewodros H Gebremariam et al.
Introduction: Lung cancer is the most common cause of cancer deaths worldwide, accounting for 1.8 million deaths each year. Only 20% of lung cancer cases are reported to occur in low- and middle-income countries. An estim...
The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis [0.03%]
免疫疗法的可获得性对III期NSCLC护理模式的影响：荷兰多中心分析
Merle I Ronden,Idris Bahce,Niels J M Claessens et al.
Merle I Ronden et al.
Introduction: Treatment patterns in stage III NSCLC can vary considerably between countries. The PACIFIC trial reported improvements in progression-free and overall survival with adjuvant durvalumab after concurrent chemo...